Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
NCT ID: NCT00776763
Last Updated: 2011-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
150 participants
INTERVENTIONAL
2008-10-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Materials: The research will be conducted on the following categories of patients groups:
* nondiabetic patients without AMD or any other diagnosed proliferative ocular disease (controls)
* patients with age related macular degeneration (AMD groups) before and after intravitreal injections with Avastin
* diabetic patients with different types of diabetic retinopathy, before and after intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids will be collected from each group of patients. 10 growth factors and other 10 cytokines will be determined in the ocular fluids samples.
Results: The results from the biochemical measurements will be statistically interpreted in order to obtain conclusions for the clinical practice.
Conclusions: The conclusions of this trial will be used exclusively for research publications and communications, as well as for clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systemic Avastin Therapy in Age-Related Macular Degeneration
NCT00531024
Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01389505
Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis
NCT01760746
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059
Intravitreal Avastin in Proliferative Retinopathies
NCT00564148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Avastin
Avastin intravitreal injection
1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avastin intravitreal injection
1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* nondiabetic patients requiring cataract surgery or vitrectomy for different posterior segment nonproliferative disorders - controls groups
* diabetic patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - diabetic groups
* diabetic patients requiring cataract surgery or vitrectomy - diabetic groups
* age related macular degeneration patients asking ophthalmologic treatments for different degrees of decreasing of visual acuity - age related macular degeneration groups
* age related macular degeneration patients requiring cataract surgery or vitrectomy - age related macular degeneration groups
Exclusion Criteria
* patients that did not accept and signed the informed consent of the trial
* patients that received any anti-VEGF therapy for any proliferative or inflammatory ocular disease
* patients that received any type of intraocular injection with any pharmaceutical agent
* patients with any clinical type of malignancy in their pathologic antecedents
* patients with recent penetrating trauma (less than 1 year old)
* patients operated for different ocular disorders requiring combination with antimetabolites (ex. 5-FU or Mitomycin C with trabeculectomy)
* patients with intraocular inflammations or infections or other pathologies that contraindicate open globe surgery or intraocular injections with anti-VEGF blockers
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Ophthalmological Association Edelweiss
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Railway Universitary Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NARCISA IANOPOL, Researcher
Role: PRINCIPAL_INVESTIGATOR
Railway Universitary Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Railway Universitary Hospital
Iași, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KIA-ProRet
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.